Johnson & Johnson’s Spravato sales growth signals upside for psychedelics peers like AtaiBeckley

Johnson & Johnson (NYSE:JNJ)’s Spravato is reinforcing investor interest in the broader psychedelics sector as it reported another quarter of strong sales...
Open original source